- Home
- VRTX vs SMFG Comparison
VRTX vs SMFG Comparison
Compare VRTX & SMFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- SMFG
- Stock Information
- Founded
- VRTX 1989
- SMFG 2002
- Country
- VRTX United States
- SMFG Japan
- Employees
- VRTX N/A
- SMFG N/A
- Industry
- VRTX EDP Services
- SMFG Commercial Banks
- Sector
- VRTX Technology
- SMFG Finance
- Exchange
- VRTX Nasdaq
- SMFG Nasdaq
- Market Cap
- VRTX 96.6B
- SMFG 103.4B
- IPO Year
- VRTX 1991
- SMFG 1949
- Fundamental
- Price
- VRTX $423.53
- SMFG $15.99
- Analyst Decision
- VRTX Buy
- SMFG
- Analyst Count
- VRTX 26
- SMFG 0
- Target Price
- VRTX $491.78
- SMFG N/A
- AVG Volume (30 Days)
- VRTX 1.4M
- SMFG 2.1M
- Earning Date
- VRTX 11-03-2025
- SMFG 11-13-2025
- Dividend Yield
- VRTX N/A
- SMFG 2.45%
- EPS Growth
- VRTX N/A
- SMFG N/A
- EPS
- VRTX 14.07
- SMFG 0.86
- Revenue
- VRTX $11,418,800,000.00
- SMFG $23,194,711,070.00
- Revenue This Year
- VRTX $10.92
- SMFG $35.65
- Revenue Next Year
- VRTX $9.55
- SMFG $3.30
- P/E Ratio
- VRTX $30.04
- SMFG $30.35
- Revenue Growth
- VRTX 10.46
- SMFG N/A
- 52 Week Low
- VRTX $362.50
- SMFG $11.83
- 52 Week High
- VRTX $519.88
- SMFG $17.46
- Technical
- Relative Strength Index (RSI)
- VRTX 61.96
- SMFG 46.73
- Support Level
- VRTX $405.54
- SMFG $15.62
- Resistance Level
- VRTX $432.76
- SMFG $16.30
- Average True Range (ATR)
- VRTX 8.97
- SMFG 0.20
- MACD
- VRTX 1.62
- SMFG 0.02
- Stochastic Oscillator
- VRTX 71.05
- SMFG 64.53
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About SMFG Sumitomo Mitsui Financial Group Inc Unsponsored (Japan)
Sumitomo Mitsui Financial Group is roughly tied with Mizuho Financial Group for the status of Japan's second-largest bank after Mitsubishi UFJ Financial Group. As of March 2024, its market share of domestic loans was 7.2%, compared with 8.0% for MUFG. It has a larger consumer finance business than the other two megabanks, owning 100% of the Promise business and SMBC Card. It also controls one of Japan's largest leasing companies and SMBC Aviation Capital, one of the top five aircraft lessors globally. In securities, its SMBC Nikko unit is Japan's third-largest retail broker, although SMFG has lagged somewhat in institutional securities business and asset management.